ALKERMES, INC.
πΊπΈUnited States
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
- First Posted Date
- 2014-06-09
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 447
- Registration Number
- NCT02158546
- Locations
- π§π¬
Alkermes Investigational Site, Vratza, Bulgaria
πΊπΈAlkermes Investigational, Washington DC, Maryland, United States
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: Low Dose ALKS 5461Drug: High Dose ALKS 5461Drug: Placebo
- First Posted Date
- 2014-06-09
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 385
- Registration Number
- NCT02158533
- Locations
- π¨π¦
Alkermes Investigational Site, Quebec, Canada
πΊπΈAlkermes, Investigational Site, Alpharetta, Georgia, United States
A Long-Term Safety Study of ALKS 5461
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 1485
- Registration Number
- NCT02141399
- Locations
- π΅π·
Alkermes Investigational Site, San Juan, Puerto Rico
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT02085135
- Locations
- π¨π¦
Alkermes Investigational Site, Halifax, Nova Scotia, Canada
A Study of ALKS 5461 in Healthy Volunteers
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT02068105
- Locations
- πΊπΈ
Alkermes Investigational Site, Overland Park, Kansas, United States
A Study of ALKS 3831 in Adults With Schizophrenia
Phase 2
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 347
- Registration Number
- NCT01903837
- Locations
- π¨πΏ
Alkermes Investigational Site, Praha, Czechia
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: ALKS 9072, High DoseDrug: ALKS 9072, Low Dose
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2017-08-25
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 291
- Registration Number
- NCT01895452
- Locations
- πΊπ¦
Roshchino township, Vinnytsia, Ukraine
πΊπ¦Alkermes Investigational Site, Ternopil, Ukraine
A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: ALKS 9072, HighDrug: ALKS 9072, Low
- First Posted Date
- 2012-06-22
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 478
- Registration Number
- NCT01626456
- Locations
- πΊπ¦
Alkermes Investigational Site, Vinnytsia, Ukraine
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 142
- Registration Number
- NCT01500200
- Locations
- πΊπΈ
Alkermes Investigational Site, Bellevue, Washington, United States
A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia
Phase 1
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: ALKS 9072, Med doseDrug: PlaceboDrug: ALKS 9072, Low doseDrug: ALKS 9072, High dose
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT01493726
- Locations
- πΊπΈ
Alkermes Investigational Site, Irving, Texas, United States
Β© Copyright 2025. All Rights Reserved by MedPath